Antimicrobial resistance is a significant problem in today's healthcare environment. Reports have predominantly targeted the hospital environment as the main source of resistant infections, such as those caused by methicillin-resistant *Staphylococcus aureus* (MRSA) “superbugs.” Resistant hospital-acquired infections are associated with substantial morbidity, mortality, and costs. This has led to the movement towards increased transparency and reduction in reimbursement for such “preventable” conditions.1

What is important to note is that the concerns pertaining to antimicrobial resistance are just as important in the outpatient setting. The call for more judicious use of antimicrobials in the primary care setting began in the 1990s when resistance rates of *Streptococcus pneumoniae* to penicillin and the macrolides were rapidly increasing.2 This was associated with a gradual reduction in the number of prescriptions by primary care physicians (PCPs) to treat upper respiratory tract infections (RTIs) in Europe.3, 4 However, this trend has not been as obvious in the United States.

• In 1998, acute RTIs were associated with over 76 million office visits resulting in 41 million antimicrobial prescriptions—55% (22.6 million) of these prescriptions were considered unnecessary since the RTIs were likely caused by viral pathogens.5

• According to a 2006 study that included 52,135 RTI-associated office visits, the percentage of patients receiving antimicrobials remains high despite that only 5%–25% of these patients may actually have a bacterial infection.6
The overuse of antimicrobials has several potential consequences, including increasing the risk of resistance development and the probability of an adverse event or drug–drug interaction while inflating overall healthcare costs. Given the number of antimicrobial prescriptions for RTIs written by PCPs, this sector of healthcare can make a major impact in reducing or minimizing resistance development in the community. Education on the proper use and selection of antimicrobials for community-acquired RTIs is imperative in reducing unnecessary antimicrobial use and, thus, minimizing the selective pressure for resistance.

This bulletin, therefore, focuses on

• When an antimicrobial is appropriate for patients who present with an RTI
• How to select the appropriate agent when a bacterial infection is suspected

This bulletin discusses lower RTIs as these are associated with more serious complications and have a greater risk of mortality. Future bulletins will discuss the impact of resistance in the community on antimicrobial selection and will offer insights on how to appropriately select and dose these agents to achieve successful clinical outcomes while minimizing the risk of resistance development.
CME ACCREDITATION

RELEASE DATE  September 9, 2009
EXPIRATION DATE  September 9, 2010

TARGET AUDIENCE
This educational initiative has been designed to meet the needs of physicians and other healthcare professionals involved in the diagnosis, management, and treatment of outpatients with RTIs.

PURPOSE STATEMENT
The purpose of this activity is to educate primary care physicians and other healthcare professionals on when an antimicrobial agent is needed to treat an RTI, identifying the risk factors for a resistant RTI, and optimizing antimicrobial therapy. With this knowledge, healthcare professionals involved in the diagnosis, management, and treatment of outpatients with RTIs will be able to tailor therapy to achieve successful outcomes.

LEARNING OBJECTIVES
At the conclusion of this activity, learners should be able to:
• Determine when an antimicrobial agent is needed to treat a respiratory tract infection (RTI)

AUTHORS
Donald E. Low, MD, FRCPC
Microbiologist-in-Chief, University Health Network/Mount Sinai Hospital
Medical Director, Public Health Laboratories
Ontario Agency for Health Protection and Promotion
Toronto, Ontario

Jerome J. Schentag, PharmD
Professor of Pharmaceutical Sciences and Pharmacy
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Buffalo, New York

William M. Simpson, Jr., MD
Professor of Family Medicine
Medical University of South Carolina
Charleston, South Carolina

PHYSICIANS
Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCMCE) through joint sponsorship of Center for Independent Healthcare Education (Center) and Vemco MedEd.

Center is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Center designates for this activity maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INSTRUCTION FOR CREDIT
1. Review the entire CME information including target audience, learning objectives, and disclosures.
2. Review this activity in its entirety.
3. Complete the Self-Assessment, Evaluation, and Credit Application form.
Or Fax to (908) 450-3300.

Documentation of credit will be mailed within 4 weeks of receipt of the completed Self-Assessment, Evaluation, and Credit Application form.

DISCLOSURE OF CONFLICTS
OF INTEREST
Center for Independent Healthcare Education requires faculty, planners, and others who are in a position to control the content of continuing education activities to disclose to the audience any real or apparent conflict of interest related to the activity. All identified conflicts of interest are reviewed to ensure balance, objectivity, and scientific rigor in all activities. The faculty is further required to disclose discussion of off-label uses.

DISCLOSURES
Faculty
Donald Low, MD
• Consultant: Roche Laboratories, Bayer Healthcare AG, Advanced Life Sciences, and Boehringer Ingelheim USA Corporation
• Research Support: Bayer Healthcare AG (Principal Investigator)

Jerome Schentag, PharmD
• Advisory Boards: Optimer, Targanta, Astellas, and Novartis.
• Consultant: Daiichi-Sanyko, Eisai, and Premier Healthcare
• Grant/Research Support: Wyeth, Astellas, and Daiichi-Sanyko
• Board Member/Shareholder: TheraSyn and CPL Associates
• Patent Holder: University of Buffalo and TheraSyn.

William Simpson, Jr., MD
• Speaker’s Bureau: Novartis and Merck

Planning Committee Members
Employees of Center for Independent Healthcare Education and Vemco MedEd have no relevant financial relationships to disclose.

Off-label Disclosure Statement
The off-label use of any antimicrobial agent is not discussed during this activity.

JOINT SPONSORSHIP
This activity is jointly sponsored by Center for Independent Healthcare Education and Vemco MedEd.

COMMERCIAL SUPPORT
This activity is supported by an educational grant from Schering-Plough Corporation.

FEE
There is no fee to participate in this educational activity.

COPYRIGHT STATEMENT
Copyright 2009© Vemco MedEd, LLC. All rights reserved.

Permission for accreditation use granted to Center for Independent Healthcare Education.

CONTACT INFORMATION
For questions regarding the accreditation of this activity, please contact Center for Independent Healthcare Education at info@jointsponsor.com.
Acute bronchitis is among the most common causes of visits to PCPs. Data from the National Health Interview Survey indicate that 4% to 5% of the adult population will have at least one episode each year. This was confirmed in a more recent study involving Oregon Medicaid patients in which approximately 5% of the population was diagnosed with acute bronchitis each year.

The primary symptom of acute bronchitis is cough lasting 21 days or less in otherwise healthy patients. (Please note that cough lasting longer than 21 days should be considered “chronic” or “persistent” and must be managed differently.) Before proceeding with the management of these patients, it is important to rule out other causes of cough, such as asthma and pneumonia.

It is important to recognize that in 90%-95% of patients, acute bronchitis is due to a viral pathogen (Table 1). Less than 10% of patients with acute bronchitis have a bacterial cause of infection and only a few bacteria have been identified as potential causative pathogens. A small proportion of patients may also have non-infectious disease causes—occult asthma and allergic or occupational exposures.

In the 90%-95% of patients with viral acute bronchitis, antimicrobials are not recommended. However, studies have shown 50%-80% antimicrobial prescription rates. Systematic reviews and meta-analyses prove no consistent effect of antimicrobials on the duration or severity of illness in these patients.

Antimicrobials are appropriate in:

- Patients suspected with pertussis infection—those exposed to a known pertussis infection or symptomatic patients during a documented pertussis epidemic.
- Patients during mycoplasma or C. pneumoniae outbreaks

When managing patients with acute bronchitis, it may be useful to refer to the illness as a “chest cold”. This will help discourage the perception that antimicrobial therapy is needed. Inhaled bronchodilators may be prescribed in some circumstances to help relieve symptoms while increase in fluid intake should be encouraged.

For those experiencing persistent irritative cough, a trial of a scopolamine-containing product should be considered.

### Table 1. Common causative pathogens of acute bronchitis

<table>
<thead>
<tr>
<th>Viral Pathogens (90%-95% of cases)</th>
<th>Bacterial Pathogens (&lt;10% of cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>Bordetella pertussis</td>
</tr>
<tr>
<td>Parainfluenza</td>
<td>Mycoplasma pneumoniae</td>
</tr>
<tr>
<td>Respiratory syncitial virus (RSV)</td>
<td>Chlamydophila pneumoniae</td>
</tr>
<tr>
<td>Coronavirus</td>
<td></td>
</tr>
<tr>
<td>Adenovirus</td>
<td></td>
</tr>
<tr>
<td>Rhinoviruses</td>
<td></td>
</tr>
</tbody>
</table>
Chronic bronchitis (defined as cough with sputum production for most days of at least 3 months a year for two consecutive years) is present in approximately 85% of the patients with chronic obstructive pulmonary disease (COPD). It can also occur in the absence of airway obstruction and therefore it is not always associated with COPD.

Defining AECB is difficult given the lack of standardized physiological, laboratory, or radiological diagnostic tests for this condition and its definition in clinical practice is varied. However, it typically involves the three cardinal criteria first established by Anthonisen and colleagues in 1987—increased sputum volume, increased sputum purulence, and increased dyspnea (Table 2). Based on these criteria, a COPD patient typically has 2 to 3 exacerbations each year. These criteria have also been used in the Canadian guidelines on AECB management to stratify patients into 3 categories—Type 1 (severe exacerbation), Type 2 (moderate exacerbation), and Type 3 (mild exacerbation) (Table 2).

### Table 2. AECB criteria and stratification

<table>
<thead>
<tr>
<th>AECB Criteria established by Anthonisen and colleagues in 1987&lt;sup&gt;16&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Increased sputum volume</td>
</tr>
<tr>
<td>2. Increased sputum purulence</td>
</tr>
<tr>
<td>3. Increased dyspnea</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AECB Stratification based on Canadian guidelines for the management of AECB&lt;sup&gt;15&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1 (severe exacerbation)</td>
</tr>
<tr>
<td>Type 2 (moderate exacerbation)</td>
</tr>
<tr>
<td>Type 3 (mild exacerbation)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
ETIOLOGY OF AECB

80% of all AECB episodes are due to viral/bacterial infections (30% due to viral and 50% due to bacterial) and only 20% are due to environmental exposure (Table 3). Antimicrobial therapy should only be considered when a bacterial infection is responsible for the AECB episode. The therapy itself depends on the specific pathogen suspected.

Table 3. Causes of AECB

<table>
<thead>
<tr>
<th>Infectious Disease (80% of all episodes)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Viral Infections</strong></td>
</tr>
<tr>
<td>• 30% of all AECB episodes</td>
</tr>
<tr>
<td><strong>Optimal Management Strategy</strong></td>
</tr>
<tr>
<td>No antimicrobial therapy</td>
</tr>
<tr>
<td><strong>Bacterial Infections</strong></td>
</tr>
<tr>
<td>50% of all AECB episodes</td>
</tr>
<tr>
<td><strong>Bacterial Etiology</strong></td>
</tr>
<tr>
<td>• Aerobic gram-positive and gram-negative pathogens (40%-50% of episodes)</td>
</tr>
<tr>
<td>- Patients with well-preserved lung function: <em>Haemophilus influenzae</em>, <em>Moraxella catarrhalis</em>, and <em>Streptococcus pneumoniae</em></td>
</tr>
<tr>
<td>- More severely ill patients with declining lung function: <em>H. influenzae</em>, <em>M. catarrhalis</em>, and <em>S. pneumoniae</em> + <em>Pseudomonas aeruginosa</em> and Enterobacteriaceae</td>
</tr>
<tr>
<td>• Atypical pathogens, primarily <em>C. pneumoniae</em> (&lt;10% of episodes)</td>
</tr>
<tr>
<td><strong>Optimal Management Strategy</strong></td>
</tr>
<tr>
<td>Antimicrobial therapy based on the pathogen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-Infectious Disease (20% of all episodes)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Environmental Exposure</strong></td>
</tr>
<tr>
<td>• Tobacco smoke</td>
</tr>
<tr>
<td>• Dust</td>
</tr>
<tr>
<td>• Allergens</td>
</tr>
<tr>
<td>• Pollutants</td>
</tr>
<tr>
<td><strong>Optimal Management Strategy</strong></td>
</tr>
<tr>
<td>• Treat the allergy</td>
</tr>
<tr>
<td>• Encourage eliminating exposure to tobacco smoke (though this can be challenging for many patients)</td>
</tr>
</tbody>
</table>
APPROPRIATE USE OF ANTIMICROBIALS FOR AECB

Early studies on the use of antimicrobials for the treatment of AECB showed little benefit when compared with placebo.\cite{18,19} However, when patients were categorized by type of symptoms, studies were able to identify those who were more likely to benefit from antimicrobial treatment.

In a randomized, double-blind study, Anthonisen and colleagues divided patients into Type 1, Type 2, and Type 3 (based on the Canadian guidelines) and compared success rates for those receiving antimicrobials (trimethoprim/sulfamethoxazole, amoxicillin, or doxycycline) versus placebo.\cite{16}

- Overall success rates were 55% in the placebo group and 68% in the antimicrobial group.
- Results stratified by type of exacerbation
  - Differences in success rate between antimicrobial and placebo groups were greatest in patients with Type 1 (severe exacerbation), while the differences were less obvious for Type 2 (moderate exacerbation) and Type 3 (mild exacerbation) (Figure 1).
  - The rate of deterioration was double in Type 1 patients receiving placebo versus those receiving antimicrobials (30.5% versus 14.3%).

\[\text{Figure 1. Success rates among patients with AECB stratified by severity}^{16}\]
Patient stratification has become an important input in deciding when an antimicrobial is necessary for managing AECB. The Canadian Thoracic Society (CTS) and the Canadian Infectious Diseases Society (CIDS) offer guidelines on how to stratify patients having a “Type 1” exacerbation to which antimicrobial should be selected (Table 4).15

<table>
<thead>
<tr>
<th>Risk Group</th>
<th>Basic Clinical State</th>
<th>Symptoms and Risk Factors</th>
<th>Antimicrobial Needed?</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Acute tracheobronchitis</td>
<td>Cough and sputum without previous pulmonary disease</td>
<td>No</td>
<td>These patients typically have a viral infection and would not require an antimicrobial unless symptoms persist for more than 10-14 days.</td>
</tr>
<tr>
<td>I</td>
<td>Chronic bronchitis without risk factors (simple)</td>
<td>Increased cough and sputum, sputum purulence, and increased dyspnea</td>
<td>Yes</td>
<td>These patients are likely to be infected with a common respiratory tract pathogen—H. influenzae, M. catarrhalis, or S. pneumoniae.</td>
</tr>
<tr>
<td>II</td>
<td>Chronic bronchitis with risk factors (complicated)</td>
<td>As in Group I + One of the following: - FEV₁&lt;50% predicted - &gt;4 exacerbations per year - Cardiac disease - Use of home oxygen - Chronic oral steroid use - Antimicrobial use in the past 3 months</td>
<td>Yes</td>
<td>These patients are more likely to be infected with an Enterobacteriaceae (such as Klebsiella pneumoniae) or P. aeruginosa, and multidrug resistance may also be a concern, particularly if there is a history of recent prior antimicrobial use. These patients may require referral to a specialist or hospital and treatment should be tailored to the specific pathogen.</td>
</tr>
<tr>
<td>III</td>
<td>Chronic suppurative bronchitis</td>
<td>As in Group II with constant purulent sputum - Some have bronchiectasis - FEV₁&lt;35% predicted - Multiple risk factors (eg, frequent exacerbations and FEV₁&lt;50% predicted)</td>
<td>Yes</td>
<td>These patients are more likely to be infected with an Enterobacteriaceae (such as Klebsiella pneumoniae) or P. aeruginosa, and multidrug resistance may also be a concern, particularly if there is a history of recent prior antimicrobial use. These patients may require referral to a specialist or hospital and treatment should be tailored to the specific pathogen.</td>
</tr>
</tbody>
</table>
COMMUNITY-ACQUIRED PNEUMONIA (CAP)

CAP is a leading cause of morbidity and mortality in the United States associated with nearly 6 million cases each year and approximately 1.5 million hospitalizations. 1, 2, 20–21 One million of these cases are attributed to those ≥65 years. 21

CAP, along with influenza, is the leading cause of death due to an infectious cause in the US. 22 Mortality rates are relatively low for outpatients with CAP (about 1%), but they increase substantially for patients requiring hospitalization (~15%) and those admitted to the ICU (30%-40%). 21 Therefore, once a diagnosis of CAP is made, it is important to first determine the appropriate site of care for the patient.

SITE OF CARE DECISION
We present two typical cases to emphasize the importance of site of care.

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>72-year-old male</td>
<td>68-year-old female</td>
</tr>
<tr>
<td>Fever: 100°F</td>
<td>Fever: 101°F</td>
</tr>
<tr>
<td>Respiratory rate: 22 per minute</td>
<td>Respiratory rate: 32 per minute</td>
</tr>
<tr>
<td>Blood pressure: 109/69 mmHg</td>
<td>Blood pressure: 109/78 mmHg</td>
</tr>
<tr>
<td>Physical findings: Rales at the right base with dullness to percussion</td>
<td>Rales at right base with dullness to percussion</td>
</tr>
<tr>
<td>Alert</td>
<td>Alert</td>
</tr>
<tr>
<td>BUN level: 25 mg/dL</td>
<td></td>
</tr>
</tbody>
</table>

Do you need to know anything else to make a decision about site of care? What do you think is the appropriate site of care for this patient?

Discussion on these cases is presented on page 13

Whether a patient requires hospitalization depends on the following factors:

1) mortality prediction tools,
2) social circumstances of the patient, and
3) co-existing conditions. 20
Several mortality prediction tools have been developed to help assess the severity of illness (Table 5).

- In the 1990s, Fine and colleagues developed the PORT (Pneumonia Outcomes Research Team) Severity Index (PSI) that used a combination of demographic variables, co-morbidities, physical observations, and laboratory and radiographic findings. However, practical application of the PSI score in primary care can be particularly difficult given the time required and the need for laboratory findings.

- The CURB-65 criteria were developed to provide a simpler and more practical tool for PCPs to help decide whether a patient can be treated as an outpatient. Though the CURB-65 criteria offers an improvement in the ease of use compared to the PSI score, there is still a laboratory requirement to assess uremia.

- The CRB-65 criteria, by eliminating the blood urea requirement, offer a more convenient tool to assess patient risk.

Table 5. CAP mortality prediction rules

<table>
<thead>
<tr>
<th>CURB-65 Score</th>
<th>Risk</th>
<th>CRB-65 Score</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 or 1</td>
<td>Low risk (Home treatment)</td>
<td>0</td>
<td>Home treatment</td>
</tr>
<tr>
<td>2</td>
<td>Moderate risk (Short inpatient stay or very closely supervised outpatient therapy)</td>
<td>1</td>
<td>Hospital-supervised treatment</td>
</tr>
<tr>
<td>3, 4, or 5</td>
<td>Severe CAP (Hospitalization; ICU admission for the most severe cases)</td>
<td>≥2</td>
<td>Hospitalization</td>
</tr>
</tbody>
</table>
A study that compared the mortality rates of patients using the PSI, CURB-65, and CRB-65 criteria showed a strong correlation among all three methods to evaluate risk for patient mortality. It is important to remember that these scores should be supplemented with the physician’s determination of several subjective factors (such as reliability to follow-up, support of family or friends, etc.) to decide whether an inpatient or outpatient stay is in the best interest of the patient.

**ETIOLOGY OF CAP**

Viral pathogens are associated with only a small proportion of CAP cases (2%-15%). S. pneumoniae remains the most common bacterial cause of CAP (20%-60%), including mild, moderate, and severe cases. Other causative bacterial pathogens include H. influenzae (3%-10%) and atypical pathogens (10%-20%).

Similar to AECB, more severe cases of CAP are predominantly due to Enterobacteriaceae and P. aeruginosa, and multidrug resistance should be considered when selecting a treatment for severe cases. The choice of initial antimicrobial therapy should, therefore, depend on the patient severity of illness, the likely pathogens, and risk of resistance and multidrug resistance. (Risk factors for resistant infections will be discussed in greater detail in Bulletin #2.)

**TREATMENT OF CAP**

In 2007, the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) released updated guidelines on the management of CAP in adults. The guidelines are a helpful resource when selecting initial empiric therapy, though antimicrobial selection should also consider patient factors and local epidemiology (Table 6).
### Outpatients

- **Previously healthy patients with no risk factors for drug-resistant *S. pneumoniae* infections**
  - Macrolide (azithromycin, clarithromycin, or erythromycin): strongly recommended
  - Doxycycline can be used as an alternative (weak recommendation)

- **Patients with comorbidities (such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs) or who had prior use of an antimicrobial within the past 3 months (in which case an alternative from a different class of agents should be selected) or other risk of a drug-resistant *S. pneumoniae* infection**
  - Respiratory fluoroquinolone (moxifloxacin, gemifloxacin*, or levofloxacin [750 mg]): strongly recommended or
  - ß-lactam + macrolide: strongly recommended

- **In regions with a high rate (>25%) of infection with high-level (≥16 µg/mL) macrolide-resistant *S. pneumoniae***
  - An alternative agent should be considered for any patient, including those without comorbidities.
    - Respiratory fluoroquinolone
    - High-dose amoxicillin
    - Amoxicillin-clavulanate
    - Ceftriaxone
    - Cefpodoxime
    - Cefuroxime
    - Doxycycline

*Note: For outpatient treatment, these recommendations should adequately cover the vast majority of CAP pathogens.* Due to the small number of *P. aeruginosa* CAP cases as well as community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) infections, clinicians should be aware of specific epidemiological patterns or clinical presentations to detect these types of infections, especially if the patient does not respond to initial therapy.

### Hospitalized Patients

- **In the general medical ward**
  - Respiratory fluoroquinolone: strongly recommended or
  - ß-lactam + macrolide: strongly recommended
  *Note: Doxycycline can be used as an alternative to a macrolide.*

- **Admitted to the ICU**
  - ß-lactam + either azithromycin or fluoroquinolone.
  - For patients suspected of *Pseudomonas* infection, an antipseudomonal ß-lactam (pipercillin-tazobactam, cefepime, imipenem, or meropenem) + either ciprofloxacin or levofloxacin (750-mg dose)

*Not currently marketed in the US*

---

**Table 6. IDSA and ATS Guidelines for the management of CAP in adults**
CASE 1 DISCUSSION

This patient likely has CAP and for complete and comprehensive evaluation using the CRB-65 criteria, you will need to assess the patient’s mental status. (To use the CURB-65 criteria, you will additionally need to conduct a laboratory blood test to evaluate renal function [BUN]).

If the mental status and BUN levels are normal, this patient will only have a score of 1 for either criteria (age >65 years), suggesting mild illness and can likely be treated on an outpatient basis. However, before discharging the patient to home care, it is important to assess his social environment and support group (family support) as well as his reliability and accessibility for follow-up.

CASE 2 DISCUSSION

CAP is suspected and the CURB-65 criteria can be used to assign a point for age, respiratory rate, and uremia. This results in a score of 3. Her CRB-65 score is 2. This patient should, therefore, be admitted to the hospital. ICU admission should be considered depending on the presence of other comorbidities.
REFERENCES


SELF-ASSESSMENT, EVALUATION, AND CREDIT APPLICATION

Select your professional title: ☐ Physician ☐ Other

Select your practice setting: ☐ Teaching hospital ☐ Community hospital ☐ LTAC ☐ Other

Your evaluation and suggestions will help improve the quality of future continuing education activities. Please answer the following general questions and provide written comments. Thank you for your cooperation.

SELF-ASSESSMENT
(Please check the most appropriate answers)

What percent of acute bronchitis episodes are caused by viral infections?
☐ 25%
☐ 50%
☐ 75%
☐ >90%

Which of the following is not a cardinal symptom of an AECB episode?
☐ Fever
☐ Increased sputum volume
☐ Increased sputum purulence
☐ Increased dyspnea

The most common bacterial cause of community-acquired pneumonia is:
☐ Haemophilus influenzae
☐ Streptococcus pneumoniae
☐ Staphylococcus aureus
☐ Moraxella catarrhalis

Which of the following is not part of the CURB-65 criteria to evaluate severity of illness in CAP patients?
☐ Respiratory rate
☐ Low blood pressure
☐ Cough
☐ Uremia

According to the 2007 IDSA/ATS guidelines, which agent is recommended for outpatient treatment of CAP in a previously healthy patient with no recent history of antimicrobial use?
☐ Penicillin
☐ Macrolide
☐ Fluoroquinolone
☐ Cephalosporin

LEARNING OBJECTIVES: Was the learning objective met? Yes Somewhat No

1. Determine when an antimicrobial agent is needed to treat a respiratory tract infection (RTI)

If you answered ‘No’, please explain why

LEARNING FORMAT
Yes Somewhat No

1. The format enhanced achievement of learning objectives.
2. The format was easy to follow and understand.

PRACTICE APPLICATION
1. What aspects of this activity were most relevant to your practice?

2. Will you make changes to your practice setting based on participation in this activity? Why or why not?

3. What aspects of RTI do you need to learn more about in order to improve your practice performance?

DO YOU HAVE (1) ANY SUGGESTIONS FOR IMPROVING THIS ACTIVITY or (2) ANY ADDITIONAL COMMENTS?

CREDIT APPLICATION (Please Print Clearly)

Address
City State ZIP
Email
May we contact you by e-mail? ☐ Yes ☐ No

Type of Credit requested: ☐ MD/DO AMA PRA Category 1 Credit™ ☐ Other

I certify that I have reviewed in its entirety RTI Resistance On the Frontline of Care: PCPs Fight Back! Bulletin 1: To Prescribe or Not: Differentiating the Need for Antimicrobials in RTIs. Signature Date